Article Text

PDF

Anti-androgen treatment immediately after surgery for prostate cancer improved survival
  1. Michael J Barry, MD
  1. Massachusetts General Hospital Boston, Massachusetts, USA

    Statistics from Altmetric.com

    
 
 QUESTION: In men with node positive prostate cancer, is survival prolonged by starting anti-androgen treatment immediately after surgery rather than delaying it until the appearance of disease progression?

    Design

    Randomised {allocation concealed*}, unblinded,* controlled trial with median 7.1 years follow up.

    Setting

    6 US university centres.

    Patients

    98 men (median age 66 y) who had clinically localised prostate cancer (≤ stage T2), had had radical prostatectomy and bilateral pelvic lymphadenectomy within the previous 12 weeks, and had histologically confirmed nodal metastases.

    Intervention

    Patients were allocated to anti-androgen treatment with either goserelin, 3.6 mg subcutaneously every 28 days, or bilateral orchiectomy (n=47) or to be followed until evidence existed of disease progression other than newly detectable or rising levels of prostate specific antigen (PSA) (n=51).

    Main outcome measures

    Death, death from prostate cancer, and recurrence.

    Main results

    Analysis was by intention to treat. At a median follow up of 7.1 years, more men in the observation group had died from any cause (hazard ratio [HR] 3.0, 95% CI 1.2 to 7.3; p=0.02) or from prostate cancer (HR 6.2, CI 1.8 to 21.5; p<0.01) than had men who received immediate antiandrogen treatment (table). Disease recurrence was greater in the observation group than in the immediate antiandrogen treatment group (HR 12.2, CI 5.1 to 29.1; p<0.001) (table). Baseline characteristics or type of anti-androgen treatment did not affect survival.

    Anti-androgen treatment immediately after surgery v observation for node positive prostate cancer at median 7.1 years follow up‡

    Conclusion

    In men with node positive prostate cancer, starting antiandrogen treatment immediately after surgery rather than delaying it until the appearance of disease progression improved survival.

    Commentary

    The study by Messing et al convincingly shows better outcomes for men who, after radical prostatectomy and pelvic lymphadenectomy, are found to have lymph node metastases and are immediately treated with androgen deprivation rather than waiting for disease progression to appear. Such men are at high risk for disease progression, even those with low PSA levels after surgery alone (only 16% of the control group in this study showed no evidence of disease progression over 7 years). These results are consistent with a trial done in the UK that also showed improved cancer specific survival for men with locally advanced or asymptomatic metastatic disease who were treated with immediate androgen deprivation. 1

    One problem with long trials is that as new technologies appear, the trials' results may be less helpful in practice than originally hoped. Currently, widespread PSA screening has resulted in a “stage shift,” with a small percentage of radical prostatectomies now associated with positive nodes.

    Most men who are started on androgen deprivation show evidence of residual or recurrent cancer after surgery or radiation treatment solely on the basis of PSA levels. Those with recurrent disease have a better prognosis than node positive patients, with a median time to a positive bone scan of 8 years without treatment. 2 As a result, competing risks become more of an issue for patients with recurrent disease than for node positive patients. Furthermore, the cumulative effects on health after years or decades of androgen deprivation are only now emerging. These consequences were reported only superficially in this study. Further trials comparing early with delayed androgen deprivation are needed before assuming that early androgen deprivation has a similar risk benefit tradeoff in men who have either early evidence of disease recurrence or prognostic factors at the time of primary treatment that suggest a major risk for future recurrence.

    References

    View Abstract

    Footnotes

    • Sources of funding: National Institutes of Health and Department of Health and Human Services.

    • For correspondence: Dr E M Messing, University of Rochester, Department of Urology, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA. Fax +1 716 442 8350.

    • * See glossary.

    • Information provided by author.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.